Seqera
Seqera is a Barcelona-based bioinformatics platform built by the creators of Nextflow, an open-source workflow orchestration tool.
Profile
Seqera provides workflow orchestration and pipeline management software for life sciences research, built on the open-source Nextflow framework, plus commercial services for cloud-native execution, governance, and AI-assisted analysis.
Seqera is a Barcelona-based bioinformatics platform built by the creators of Nextflow, an open-source workflow orchestration tool. Founded in 2018 by Evan Floden and Paolo Di Tommaso—who developed Nextflow in 2013 while researchers at the Centre for Genomic Regulation—Seqera spun out to commercialize workflow software for life sciences. The platform combines open-source Nextflow orchestration with proprietary commercial services: Tower/Seqera Platform for pipeline management and governance, Wave Containers for reproducibility, and a newly launched Co-Scientist AI assistant.
Seqera has grown to approximately 110 employees and secured $53.2 million in funding, including a $26 million Series B round led by Addition in May 2025. The company reports 150+ enterprise customers—8 of the top 20 global pharmaceutical firms among them—including AstraZeneca, Roche, Janssen Pharmaceuticals, and Oxford Nanopore. Nextflow itself has over 25,000 users and 160,000 monthly downloads, with Seqera Cloud hosting 9,000+ users.
In 2025–2026, the company launched Seqera Compute (managed cloud orchestration), Co-Scientist (AI-driven pipeline assistance), and Intelligent Compute (cloud-native pipeline scaling). The market for workflow orchestration in biotech is fragmented—dominated by general tools like Apache Airflow and scientific alternatives like Snakemake and Cromwell—but Seqera's advantage lies in close integration with open-source Nextflow and a customer base concentrated in pharmaceutical and genomics R&D. Recent announcements emphasize AI-native tools, enterprise compliance (GxP versioning), and data exploration features.
Who buys this
- Pharmaceutical and biotech R&D teams running genomics, drug discovery, and clinical diagnostics pipelines
- Academic and government research institutions with high-performance computing and compliance requirements
- Contract research organizations and clinical laboratories analyzing genomic and molecular data
- In vitro diagnostics and precision medicine companies scaling sequencing workflows
Publicly disclosed clients
- AstraZeneca
- Roche
- Janssen Pharmaceuticals
- Oxford Nanopore
- Invitae
- Bio-Rad Laboratories
Strengths and what to watch
Strengths
- Tight integration between open-source Nextflow and commercial Seqera Platform reduces vendor lock-in and enables hybrid deployment across on-premises, multi-cloud, and HPC environments.
- Customer base of 150+ enterprise clients with 8 of the top 20 global pharmaceutical firms, generating strong reference ability and retention in high-stakes R&D settings.
- Nextflow ecosystem of 25,000+ users and 1,900+ open-source contributors creates a de facto standard for reproducible scientific workflows, particularly in genomics.
Watch for
- Nextflow plugin registry governance: community controversy in 2024–2025 over Seqera's terms of use and plugin licensing raised concerns about open-source autonomy; company clarified it will not restrict community plugins, but ongoing compliance alignment matters.
- High customer concentration in pharma and biotech; economic downturn or consolidation in those sectors could impact revenue concentration.
- AI feature competition: Co-Scientist AI (launched 2026) competes with LLM-assisted competitors and general-purpose tools; differentiation and adoption velocity will determine market share growth.
Recent moves
Key Information
- Industry
- Infrastructure - Orchestration
- Founded
- 2018
- Headquarters
- Barcelona, Country
Frequently Asked Questions
What is Seqera?
Seqera is a Barcelona-based bioinformatics platform providing workflow orchestration and pipeline management for life sciences. Built by Nextflow's creators, it combines open-source Nextflow with commercial services: Seqera Platform for governance, Wave Containers for reproducibility, and Co-Scientist AI for analysis automation.
How many enterprise customers does Seqera have?
Seqera serves 150+ enterprise customers, including 8 of the top 20 global pharmaceutical firms: AstraZeneca, Roche, Janssen Pharmaceuticals, and Oxford Nanopore. The underlying Nextflow ecosystem has 25,000+ users generating 160,000 monthly downloads, while Seqera Cloud hosts 9,000+ users.
What is Nextflow?
Nextflow is an open-source workflow orchestration framework created by Seqera's founders in 2013 at the Centre for Genomic Regulation. It enables reproducible scientific workflows across on-premises, multi-cloud, and high-performance computing environments, serving as the foundation for Seqera's commercial platform.
What are Seqera's three main products?
Seqera Platform (formerly Tower) manages workflows and governance; Wave Containers enables reproducible containerization; Co-Scientist, launched 2026, is an AI assistant providing self-service optimization, interactive research intelligence, and autonomous agents for genomics and molecular data analysis automation.
Who should use Seqera?
Seqera targets pharmaceutical R&D, biotech firms, academic institutions, and clinical laboratories. It suits teams running genomics pipelines, drug discovery workflows, clinical diagnostics, or sequencing analysis at scale, especially those needing reproducible, compliant, enterprise-grade management across hybrid infrastructure.
What is Seqera Co-Scientist?
Co-Scientist is Seqera's AI-driven pipeline assistant launched in 2026. It provides self-service pipeline optimization, interactive research intelligence for data exploration, and autonomous agent automation. Co-Scientist accelerates genomics and molecular workflows without requiring deep pipeline engineering expertise.
How Seqera compares
Direct head-to-head against 2 competitors. Picked by 7wData.
Seqera
- Positioning
- Seqera provides workflow orchestration and pipeline management software for life sciences research, built on the open-source Nextflow framework, plus commercial services for cloud-native execution, governance, and AI-assisted analysis.
- Customer segments
- Pharmaceutical and biotech R&D teams running genomics, drug discovery, and clinical diagnostics pipelines
- Strengths
- Tight integration between open-source Nextflow and commercial Seqera Platform reduces vendor lock-in and enables hybrid deployment across on-premises, multi-cloud, and HPC environments.
- Watch for
- Nextflow plugin registry governance: community controversy in 2024–2025 over Seqera's terms of use and plugin licensing raised concerns about open-source autonomy; company clarified it will not restrict community plugins, but ongoing compliance alignment matters.
- Recent moves
- Seqera launches Co-Scientist AI and Intelligent Compute at Nextflow Summit Boston 2026
DNAnexus
- Positioning
- Cloud platform for petabyte-scale genomic data management, analysis, and pipeline orchestration in regulated life sciences.
- Customer segments
- Biopharma R&D teams, clinical labs, population genomics programs. Buyer: VP Bioinformatics, IT Director.
- Strengths
- GxP-compliant pipeline orchestration at scale, validated by UK Biobank and tier-1 pharma (Eli Lilly, City of Hope).
- Watch for
- Glassdoor reviews cite key technical staff departures, describing the company as a hollow version of its former self.
- Recent moves
- May 2026: launched Omics Data Agent (cohort query interface) and AutoML Assistant, claiming 80 percent faster time-to-model.
Velsera (Seven Bridges)
- Positioning
- PE-backed roll-up covering cloud bioinformatics pipelines, clinical variant reporting, and real-world data access for precision medicine.
- Customer segments
- Pharma drug discovery teams, clinical oncology labs, government genomics programs (NCI). Buyer: Head of Bioinformatics, Lab Director.
- Strengths
- Operates NCI Cancer Genomics Cloud contract and supports CWL-portable pipelines across 800-plus curated workflow apps.
- Watch for
- Glassdoor rating of 2.4 out of 5 includes accounts of neglected founding products and customers leaving at contract renewal.
- Recent moves
- February 2026: Jamie Coffin appointed CEO, the second leadership change since the 2023 three-way merger under Summa Equity.
Sources
- seqera.io — Company mission, products (Pipelines, Containers, Co-Scientist), customer logos
- seqera.io — Founders (Evan Floden, Paolo Di Tommaso), founding year (2018), employee count (100+), leadership team, Nextflow origin story
- seqera.io — Series B funding: $26M, May 6, 2025, led by Addition, with Speedinvest, Talis, Amino Collective, BoxOne, SNR; strategic direction on cloud-native pipelines and AI tools
- bist.eu — Series A funding: €22M, October 2022, investors (Addition, Speedinvest, Talis, BoxOne, Amino); CRG intellectual property agreement
- www.crunchbase.com — Total funding of $53.2M, funding timeline, investors
- aws.amazon.com — Seqera Platform AWS integration and customer use cases
- seqera.io — Co-Scientist AI feature launch 2026, capabilities (self-service, interactive research intelligence, autonomous agents)
- seqera.io — Customer adoption metrics: 150+ enterprise customers, 20,000+ Nextflow users, 8 of top 20 pharma firms